Insights & Perspectives
Commercial strategy perspectives for diagnostics, precision medicine, and life science companies navigating the path from scientific promise to clinical adoption, reimbursement, market access, and revenue growth.
Featured Insight
Robert Carlson · May 2026
Scientific progress is not commercial readiness. A compelling diagnostic technology can still fail commercially if the company has not defined the clinical decision, evidence burden, coding pathway, reimbursement strategy, workflow fit, physician adoption model, and commercial execution plan.
More Insights
Robert Carlson · June 2026
Diagnostic adoption depends on whether patient, physician, operational, laboratory, reimbursement, reporting, and commercial workflows can work together in routine care.
Robert Carlson · July 2026
Scientific validation creates credibility. Clinical utility supports adoption, reimbursement, and commercial relevance.
Robert Carlson · August 2026
Regulatory clearance may allow market entry. Reimbursement determines whether a diagnostic test can be adopted, paid for, and used in a commercially sustainable way.
Robert Carlson · September 2026
The economics of molecular diagnostics have fundamentally shifted. More testing options, more payer scrutiny, and more complex reimbursement pathways mean that economic strategy must be built alongside clinical strategy from the start.
Work With Life Science Dx
Life Science Dx works with diagnostics, precision medicine, and life science companies navigating commercialization, market access, reimbursement, clinical utility, adoption, partnership, and growth questions.